RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) -- PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a...